Thomas’ Bill: Can a Father's Legacy Fix Canada's Psychedelic Gridlock?

TORONTO, ON – June 16, 2026 – For Thomas Hartle, psilocybin therapy was not an experiment; it was a lifeline. Diagnosed with stage IV colon cancer in 2016, the Saskatchewan father faced unimaginable end-of-life anxiety. In 2020, he made history as the first Canadian granted a legal exemption to use psilocybin-assisted therapy. The results were immediate and profound. His wife, Marliss, recounted how the treatment lifted the suffocating weight of his anxiety, allowing him to be present with his family during his final years. He became a passionate advocate, a living testament to the therapy's potential.

But the system that offered him hope ultimately failed him. When his exemption expired, his renewal request languished in bureaucratic limbo for 511 days, only to be denied. A dying man was forced to spend his precious final months fighting for access to a treatment that had already proven to restore his peace of mind. Hartle passed away in August 2024, his struggle becoming a tragic symbol of a system described by advocates as broken, slow, and inhumane.

Today, his legacy is being carried into the halls of Parliament. Bill C-286, a private member's bill introduced by Saskatchewan MP Corey Tochor, bears his name. Dubbed “Thomas’ Bill,” the legislation seeks to carve a new path for medical psilocybin access in Canada, one that proponents hope will replace bureaucratic gridlock with regulated, compassionate care.

A System Under Strain

At the heart of the issue is Health Canada's Special Access Program (SAP), the primary mechanism for patients to obtain unapproved drugs like psilocybin. While the program has been a gateway for some since 2022, data reveals a system buckling under pressure. PsyCan, the trade association for Canada’s legal psychedelics sector, has voiced alarm over plummeting approval rates and ballooning wait times. According to records obtained by the industry group, SAP approvals for psychedelic therapies have fallen dramatically, with recent data suggesting an approval rate of just 30%.

“At a time when communities across the country continue to face unprecedented rates of depression, anxiety, trauma, addiction, and overdose, Thomas’ Bill is an important and overdue step toward modernizing Canada’s approach to medical psilocybin access,” said Austin Miller, Chair of PsyCan’s Board of Directors, in a statement supporting the bill. He stressed that Canadians deserve policies “grounded in evidence, compassion, and public health.”

Bill C-286 proposes a fundamental shift. Rather than relying on a slow, case-by-case exemption system, it would amend the Controlled Drugs and Substances Act to move psilocybin and psilocin into an existing controlled-drug medical framework. This would allow physicians to prescribe the therapy for conditions like depression, PTSD, and end-of-life distress, similar to other controlled medicines. The bill also mandates a priority review for new drug submissions involving psilocybin, aiming to accelerate research and formal approval without circumventing Health Canada's rigorous safety and efficacy standards.

For patients and practitioners, this could transform a process currently defined by uncertainty into a predictable, regulated pathway. “The clinical evidence for psilocybin-assisted therapy in palliative care is not emerging; it is established,” noted one clinical researcher with an advocacy group that supported Hartle. “Our legislation must catch up.”

The Global Race for a New Therapeutic Frontier

Canada’s struggle with psychedelic regulation is not happening in a vacuum. While Ottawa hesitates, other nations are moving decisively to integrate these promising therapies into their healthcare systems, creating a potential innovation and care gap. In 2023, Australia became one of the first countries to formally recognize psilocybin as a medicine, rescheduling it to allow authorized psychiatrists to prescribe it for treatment-resistant depression.

Meanwhile, the United States Food and Drug Administration (FDA) has taken a proactive role. Last year, it issued its first-ever draft guidance for clinical trials involving psychedelic drugs, creating a clear and structured pathway for researchers and developers. With MDMA and psilocybin in late-stage trials for PTSD and depression, respectively, the US is on a clear trajectory toward formal drug approval. This regulatory clarity has galvanized investment and research, positioning the US as a potential leader in the burgeoning field.

This leaves Canada at a strategic crossroads. The country was once seen as a pioneer, particularly after legalizing cannabis. However, its current ad-hoc approach to psychedelics risks ceding leadership and, more importantly, failing to provide its citizens with therapies available elsewhere. Industry experts warn that without reform, Canada will not only fall behind its allies but also miss a significant opportunity to build a robust domestic sector around these novel treatments. As one analyst noted, the economic and therapeutic potential is immense, but it hinges entirely on a modern and functional regulatory framework.

A Path Through Parliament

As a private member's bill, the legislative journey for Thomas’ Bill is inherently challenging, often requiring broad cross-party support to succeed. However, the issue of mental health and the need for new treatment options is gaining traction across the political spectrum. The bill's introduction by a Conservative MP, Corey Tochor, and the existence of a similar bill from Liberal MP Marcus Powlowski aimed at reducing bureaucratic delays, suggest a growing, non-partisan consensus that the status quo is untenable.

MP Tochor has framed his bill as a “common-sense step” to offer hope to Canadians, including veterans, struggling with severe mental health challenges. Public sentiment appears to be aligned. A 2025 poll commissioned by PsyCan found that a majority of Canadians support allowing the use of natural psilocybin medicines under medical supervision.

The bill's success will likely depend on the combined force of patient stories, scientific evidence, and persistent advocacy. The memory of Thomas Hartle’s fight provides a powerful moral imperative. The question now is whether that imperative is strong enough to compel Parliament to act, transforming a story of personal tragedy into a legacy of lasting, systemic change for countless others.